Humana Inc. (NYSE:HUM - Get Free Report) was down 9.1% on Wednesday. The stock traded as low as $409.25 and last traded at $403.12. Approximately 605,237 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 1,647,300 shares. The stock had previously closed at $443.34.
Key Headlines Impacting Humana
These are some of the HUM headlines that stood out recently:
- Positive Sentiment: Royal Bank of Canada upgraded Humana to “Outperform,” adding to a generally favorable analyst backdrop. Article: Royal Bank of Canada Upgrades Humana to Outperform
- Positive Sentiment: Humana recently raised its 2026 adjusted EPS outlook to at least $9.50. Its new national “Gold Card” program, intended to reduce prior-authorization requirements for some providers, may also improve administrative efficiency. Article: Humana to Launch National Gold Card Program
- Negative Sentiment: The main pressure is CMS’s proposed CRUSH rule, which would strengthen Medicare Advantage risk-adjustment audits and allow broader recovery of unsupported payments through extrapolation. CMS estimates the measure could generate about $9 billion in collections per payment year; Humana’s exposure is significant given its large Medicare Advantage membership. The proposal is not final, but it raises concerns about potential liabilities and tighter oversight. Article: Medicare Advantage audit proposal pressures insurers
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the stock. Guggenheim raised their price objective on shares of Humana from $471.00 to $521.00 and gave the stock a "buy" rating in a research report on Monday, November 9th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Humana in a report on Thursday, November 12th. William Blair initiated coverage on Humana in a research note on Monday. They issued an "outperform" rating for the company. Piper Sandler boosted their price target on shares of Humana from $463.00 to $526.00 and gave the company an "overweight" rating in a research report on Monday, November 9th. Finally, Royal Bank Of Canada set a $515.00 target price on Humana in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Humana presently has an average rating of "Moderate Buy" and a consensus price target of $484.78.
Check Out Our Latest Research Report on HUM
Humana Stock Down 10.4%
The firm has a market cap of $47.69 billion, a P/E ratio of 38.71, a P/E/G ratio of 2.20 and a beta of 0.65. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.61. The business has a 50-day moving average price of $410.55 and a 200-day moving average price of $319.48.
Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.30. Humana had a net margin of 0.81% and a return on equity of 8.50%. The business had revenue of $41.16 billion for the quarter, compared to analyst estimates of $40.87 billion. During the same period in the previous year, the company earned $3.24 earnings per share. The business's revenue for the quarter was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. On average, equities analysts forecast that Humana Inc. will post 9.66 EPS for the current fiscal year.
Humana Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be given a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, December 24th. Humana's dividend payout ratio is currently 34.44%.
Insider Activity at Humana
In related news, insider Joseph Ventura sold 5,495 shares of the business's stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the sale, the insider owned 21,910 shares of the company's stock, valued at approximately $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.20% of the stock is owned by company insiders.
Hedge Funds Weigh In On Humana
A number of institutional investors have recently modified their holdings of HUM. BlackRock Inc. purchased a new position in Humana during the 2nd quarter valued at about $4,138,160,000. State Street Corp grew its holdings in Humana by 1.6% during the 3rd quarter. State Street Corp now owns 5,543,942 shares of the insurance provider's stock worth $2,115,402,000 after acquiring an additional 86,870 shares during the last quarter. Pzena Investment Management LLC acquired a new stake in shares of Humana in the second quarter valued at approximately $1,749,014,000. Assenagon Asset Management S.A. lifted its stake in shares of Humana by 20,126.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider's stock valued at $479,053,000 after acquiring an additional 1,249,272 shares during the period. Finally, Legal & General Group Plc acquired a new position in Humana in the second quarter valued at approximately $329,760,000. Institutional investors and hedge funds own 92.38% of the company's stock.
Humana Company Profile
(
Get Free Report)
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.